Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapy

GLP1 receptor agonists for Wolfram syndrome?

Nature Reviews Endocrinology volume 19, page 313 (2023)Cite this article

Subjects

A new study in Diabetologia used human preclinical models to show the potential of glucagon-like peptide 1 receptor agonists (GLP1RAs) to treat Wolfram syndrome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Related article

  • Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201–216 (2023)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Endocrinology http://www.nature.com/nrendo/

    Shimona Starling

Authors
  1. Shimona Starling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shimona Starling.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Starling, S. GLP1 receptor agonists for Wolfram syndrome?. Nat Rev Endocrinol 19, 313 (2023). https://doi.org/10.1038/s41574-023-00839-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-023-00839-y

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing